PHYSICAL THERAPY IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH): RESULTS FROM A GERMAN CLAIMS DATA ANALYSIS

被引：0
|
作者：
Barthuber, L. [1 ]
Nill, I [1 ]
Jacob, C. [2 ]
Schmid, T. [1 ]
机构：
[1] MSD Sharp & Dohme GmbH, Munich, By, Germany
[2] Xcenda GmbH, Hannover, Germany
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
HSD44
引用
收藏
页码：S334 / S334
页数：1
相关论文
共 50 条
  • [31] Effect of Riociguat on Pulmonary Arterial Compliance in Patients With Pulmonary Arterial Hypertension (PAH) in the Respite Study
    Thenappan, Thenappan
    Hoeper, Marius
    Corris, Paul
    Ghofrani, Hossein-Ardeschir
    Klinger, James
    Langleben, David
    Naeije, Robert
    Simonneau, Gerald
    Jansa, Pavel
    Rosenkranz, Stephan
    Grunig, Ekkehard
    Scelsi, Laura
    Meier, Christian
    Busse, Dennis
    Benza, Raymond
    CHEST, 2017, 152 (04) : 1005A - 1006A
  • [32] Prevalence of Pulmonary Arterial Hypertension (PAH) in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    Villar, Adolfo
    Ancochea, Julio
    Xaubet, Antonio
    CHEST, 2014, 145 (03)
  • [33] Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH): Results From the Phase 2 TORREY Trial
    Frantz, R. P.
    McLaughlin, V. V.
    Sahay, S.
    Subias, P. Escribano
    Zolty, R. L.
    Benza, R. L.
    Channick, R. N.
    Chin, K. M.
    Hemnes, A. R.
    Howard, L. S.
    Sitbon, O.
    Vachiery, J.
    Zamanian, R. T.
    Cravets, M.
    Roscigno, R. F.
    Mottola, D.
    Elman, E.
    Parsley, E.
    Aranda, R.
    Zisman, L. S.
    Ghofrani, H.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [34] Lung transplantation in pulmonary arterial hypertension (PAH): survival analysis according to PAH risk
    Ortega, M. Zapata
    Lopez, E. Revilla
    Gimenez, B. Saez
    Garcia, C. Berastegui
    Peris, M. Arjona
    Torres, V. Monforte
    Masgoret, C. Bravo
    Ribas, E. Domingo
    Meseguer, M. Lopez
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [35] Initial combination of macitentan and tadalafil in newly diagnosed patients with pulmonary arterial hypertension (PAH): results from the OPTIMA study
    Sitbon, Olivier
    Canuet, Matthieu
    Picard, Francois
    Prevot, Gregoire
    Bergot, Emmanuel
    Cottin, Vincent
    Bauer, Fabrice
    Degano, Bruno
    Gressin, Virginie
    Clerson, Pierre
    Simonneau, Gerald
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [36] Anticoagulant Therapy Is Not Associated with Long Term Outcome in Patients with Pulmonary Arterial Hypertension (PAH): Insights from the GRIPHON Study
    Tapson, V. F.
    Channick, R.
    Chin, K.
    Di Scala, L.
    Farber, H.
    Gaine, S.
    Galie, N.
    Ghofrani, H. A.
    Lang, I.
    McLaughlin, V.
    Preiss, R.
    Rubin, L. J.
    Simonneau, G.
    Sitbon, O.
    Hoeper, M. M.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2016, 35 (04): : S120 - S120
  • [37] TREATMENT HISTORY, HEALTHCARE RESOURCE USE, AND COSTS AMONG PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) INITIATING TREATMENT WITH MACITENTAN: A RETROSPECTIVE CLAIMS ANALYSIS
    Worden, C.
    Healey, B.
    Nguyen, A. T.
    Sacks, N.
    Strachan, P.
    VALUE IN HEALTH, 2024, 27 (06) : S25 - S26
  • [38] Safety and efficacy of sitaxsentan in elderly patients with Pulmonary Arterial Hypertension (PAH)
    Vachiery, J. L.
    Sandoval-Zarate, J.
    Keogh, A.
    Kramer, M. R.
    Barst, R. J.
    Naeije, R.
    EUROPEAN HEART JOURNAL, 2006, 27 : 623 - 623
  • [39] Left Ventricular Diastolic Dysfunction in Patients With Pulmonary Arterial Hypertension (PAH)
    Dadfarmay, Sina
    Alhaj, Eyad
    Manchikalapudi, Rama Bindu
    Satya, Kumar
    Berkowitz, Robert
    JOURNAL OF CARDIAC FAILURE, 2010, 16 (08) : S19 - S19
  • [40] Economic Burden of Delayed Diagnosis in Patients with Pulmonary Arterial Hypertension (PAH)
    Dubrock, Hilary M.
    Germack, Hayley D.
    Gauthier-Loiselle, Marjolaine
    Linder, Joerg
    Satija, Ambika
    Manceur, Ameur M.
    Cloutier, Martin
    Lefebvre, Patrick
    Panjabi, Sumeet
    Frantz, Robert P.
    PHARMACOECONOMICS-OPEN, 2024, 8 (01) : 133 - 146
12345